jump to content

Fachbereich Veterinärmedizin


Service-Navigation

    Publication Database

    An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission (2024)

    Art
    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Autoren
    Adler, Julia M. (WE 5)
    Vidal, Ricardo Martin (WE 5)
    Langner, Christine (WE 5)
    Vladimirova, Daria (WE 5)
    Abdelgawad, Azza (WE 5)
    Kunecova, Daniela (WE 5)
    Lin, Xiaoyuan (WE 5)
    Nouailles, Geraldine
    Voss, Anne (WE 12)
    Kunder, Sandra (WE 12)
    Gruber, Achim D. (WE 12)
    Wu, Haibo
    Osterrieder, Nikolaus (WE 5)
    Kunec, Dusan (WE 5)
    Trimpert, Jakob (WE 5)
    Quelle
    Nature Communications
    Bandzählung: 15
    Seiten: Artikelnummer: 995
    ISSN: 2041-1723
    Sprache
    Englisch
    Verweise
    URL (Volltext): https://www.nature.com/articles/s41467-024-45348-2
    DOI: 10.1038/s41467-024-45348-2
    Pubmed: 38307868
    Kontakt
    Institut für Tierpathologie

    Robert-von-Ostertag-Str. 15
    14163 Berlin
    +49 30 838 62450
    pathologie@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    The development of effective SARS-CoV-2 vaccines has been essential to control COVID-19, but significant challenges remain. One problem is intramuscular administration, which does not induce robust mucosal immune responses in the upper airways-the primary site of infection and virus shedding. Here we compare the efficacy of a mucosal, replication-competent yet fully attenuated virus vaccine, sCPD9-ΔFCS, and the monovalent mRNA vaccine BNT162b2 in preventing transmission of SARS-CoV-2 variants B.1 and Omicron BA.5 in two scenarios. Firstly, we assessed the protective efficacy of the vaccines by exposing vaccinated male Syrian hamsters to infected counterparts. Secondly, we evaluated transmission of the challenge virus from vaccinated and subsequently challenged male hamsters to naïve contacts. Our findings demonstrate that the live-attenuated vaccine (LAV) sCPD9-ΔFCS significantly outperformed the mRNA vaccine in preventing virus transmission in both scenarios. Our results provide evidence for the advantages of locally administered LAVs over intramuscularly administered mRNA vaccines in preventing infection and reducing virus transmission.